Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
Abstract Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune...
Guardado en:
Autores principales: | Eva Serrano-Candelas, Rubén Martínez-Aranguren, Olga Vega, Gabriel Gastaminza, Joan Bartra, Maria Teresa Audicana, Jorge M. Núñez-Córdoba, Jaime Algorta, Antonio Valero, Margarita Martin, Marta Ferrer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/995bf92164984868a3e21c2d3ca0244e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Davide Stefano Sardina, et al.
Publicado: (2021) -
Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
por: Catherine King, et al.
Publicado: (2021) -
Biomarkers of Gut Microbiota in Chronic Spontaneous Urticaria and Symptomatic Dermographism
por: Runqiu Liu, et al.
Publicado: (2021) -
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Luke F. Pennington, et al.
Publicado: (2016) -
Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients
por: Duy Le Pham, et al.
Publicado: (2017)